Identification and Isolation of a 140 Kd Cell Surface Glycoprotein with Properties Expected of a Fibronectin Receptor
Overview
Authors
Affiliations
Affinity chromatography was used to identify a putative cell surface receptor for fibronectin. A large cell-attachment-promoting fibronectin fragment was used as the affinity matrix, and specific elution was effected by using synthetic peptides containing the sequence Arg-Gly-Asp, which is derived from the cell recognition sequence in the fibronectin cell attachment site. A 140 kd protein was bound by the affinity matrix from octylglucoside extracts of MG-63 human osteosarcoma cells and specifically eluted with the synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro. The 140 kd protein was labeled by cell surface specific radioiodination and became incorporated into liposomes at a high efficiency. Liposomes containing this protein showed specific affinity toward fibronectin-coated surfaces, and this binding could be selectively inhibited by the synthetic cell-attachment peptide but not by inactive peptides. Affinity chromatography on wheat germ agglutinin-Sepharose showed that the 140 kd protein is a glycoprotein and, in combination with the fibronectin fragment chromatography, gave highly enriched preparations of the 140 kd protein. These properties suggest that the 140 kd glycoprotein is a membrane-embedded cell surface protein directly involved in the initial step of cell adhesion to fibronectin substrates.
The novel ECM protein SNED1 mediates cell adhesion via the RGD-binding integrins α5β1 and αvβ3.
Pally D, Kapoor N, Naba A J Cell Sci. 2024; 138(2).
PMID: 39713860 PMC: 11828466. DOI: 10.1242/jcs.263479.
Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems.
Nikitovic D, Kukovyakina E, Berdiaki A, Tzanakakis A, Luss A, Vlaskina E Cancers (Basel). 2024; 16(22).
PMID: 39594723 PMC: 11592346. DOI: 10.3390/cancers16223768.
Polypeptides-Based Nanocarriers in Tumor Therapy.
You J, Guo Y, Dong Z Pharmaceutics. 2024; 16(9).
PMID: 39339228 PMC: 11435007. DOI: 10.3390/pharmaceutics16091192.
Biomimetic strategies for the deputization of proteoglycan functions.
Rehan I, Elnagar A, Zigo F, Sayed-Ahmed A, Yamada S Front Cell Dev Biol. 2024; 12:1391769.
PMID: 39170918 PMC: 11337302. DOI: 10.3389/fcell.2024.1391769.
Translational pathology in drug discovery.
Cuzic S, Antolic M, Ognjenovic A, Milutinovic V, Ivis S, Glojnaric I Front Pharmacol. 2024; 15:1409092.
PMID: 38915468 PMC: 11194691. DOI: 10.3389/fphar.2024.1409092.